Moody’s Analytics and Allvue Launch Credit Risk Model to Identify Early Signs of Borrower Stress in Private Credit October 1, 2026 Moody’s Analytics EDF-X Private Credit Model, powered by Allvue data, gives investors and lenders an earlier view of borrower stress in a rapidly growing market
MidOcean Concludes 2026 Equity Raise, Securing More Than $4 Billion of Equity Commitments to Accelerate Global LNG Growth Strategy October 1, 2026 MidOcean Energy (“MidOcean” or the “Company”), a liquefied natural gas (LNG) company formed and managed by EIG, today announced the conclusion of its 2026 equity capital raise, securing more than $4 billion of closed and pending commitments over the last 12 months from new strategic and institutional investors, as well as significant re-ups from existing [...]
NICE issues final draft guidance recommending ▼ Tryngolza® (olezarsen) as an option to treat genetically confirmed familial chylomicronaemia syndrome (FCS) in adults in England and Wales October 1, 2026 FOR UK HEALTHCARE/TRADE MEDIA ONLY Sobi® UK today announced that the National Institute for Health and Care Excellence (NICE) has issued final draft guidance which recommends Tryngolza® (olezarsen) as an option to treat genetically confirmed familial chylomicronaemia syndrome (FCS) in adults in England and Wales, only if response to diet and conventional triglyceride-lowering treatments (such [...]
Powerful Medical and corpuls Partner to Bring Queen of Hearts AI-Powered Heart Attack Detection to Prehospital Care October 1, 2026 Queen of Hearts, the AI ECG model that detects heart attacks standard criteria miss, will be integrated into corpuls devices and telemedicine systems used by emergency care professionals in over 70 countries globally
Hims & Hers Names Chief Medical Officers in the UK and Australia, Deepening its Investment in Local Clinical Leadership October 1, 2026 Kultar Garcha, MD, joins as Chief Medical Officer of the UK and EMEA, and Matt Vickers, FRACGP, MBBS, BMedSci, AICGG, is named Chief Medical Officer of Hims Australia, guiding clinical strategy as Hims & Hers continues to expand internationally
Telekom Srbija (Group) Is Building City-Scale Digital Infrastructure for EXPO 2027 October 1, 2026 On a site that will function, in terms of capacity, as an entirely new urban district, with more than 46 kilometres of fibre-optic network, 35 radio sites, 5G Standalone and Wi-Fi 7, Telekom Srbija Group is presenting the digital ecosystem it is building for over 135 participating countries and four million expected visitors. Telekom Srbija sees EXPO 2027 as a platform for strengthening its global positioning and marketing its products and services.
ROYC Group Launches ROYC Operating System as a Standalone Enterprise Software Platform October 1, 2026 ROYC Group today announced the launch of ROYC Operating System (ROYC OS) as a standalone software platform for fund managers, banks and wealth managers across private markets. The software is now available separately from ROYC’s existing structuring, fund operations and distribution services. Proven in production, at scale ROYC used its structuring and fund operations experience [...]
Dunbar Pharma Supplies API for UK’s First Plant-Derived Dronabinol Oral Spray October 1, 2026 Irish manufacturer’s API used in additional oral formulation through IPS Pharma; Company to expand Athlone production in 2027
EADV 2026: Long-Term Disease Control for up to Five Years in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Lebrikizumab October 1, 2026 Late-breaking results from the Phase 3b ADlong clinical study presented by Almirall at EADV 2026 show treatment outcomes over time with up to five years of lebrikizumab treatment in moderate-to-severe atopic dermatitis: sustained efficacy and safety demonstrated by 92.9% of patients achieving EASI-75 and 73.8% achieving EASI-90 at the end of the study (week 108)1. At week 108 of continuous treatment, 66.7% of patients achieved clear or almost-clear skin, while 78.0% reported an absolute pruritus score of four or less on the Pruritus Numerical Rating Scale1, indicating low levels of itch, one of the most bothersome symptoms for patients. The ADlong study reflects the ongoing commitment to generating long-term evidence for lebrikizumab and the opportunity to achieve long-term disease control in AD treatment. Almirall’s scientific presence at EADV 2026 includes more than 20 abstracts across atopic dermatitis, psoriasis and actinic keratosis, alongside three expert-led events: two symposia and an interactive AD Morning Hub.
Ares Strengthens Commitment to Plenitude Through €1 Billion Capital Contribution October 1, 2026 Reorganization of Plenitude’s capital structure expands Ares’ economic and governance participation in the company
